Nitin Mohan

Publications (2)58.02 Total impact

• Article: Meningococcal group A, C, Y and W-135 conjugate vaccine.

  Lee H Harrison, Nitin Mohan, Peter Kirkpatrick
  [show abstract] [hide abstract]
  ABSTRACT: In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.
  dressNature Reviews Drug Discovery 06/2010; 9(6):429-30. · 29.01 Impact Factor
• Article: Fresh from the Pipeline: Meningococcal group A, C, Y and W-135 conjugate vaccine

  Lee H. Harrison, Nitin Mohan, Peter Kirkpatrick
  [show abstract] [hide abstract]
  ABSTRACT: In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11–55 years.
  dressNature Reviews Drug Discovery 05/2010; 9(6):429-430. · 29.01 Impact Factor